SecBot SecBot
PRESS-RELEASE ·Filed Mar 16, 2026

AMRN

Amarin Corporation plc
NEUTRAL
Impact 4/10
Horizonweeks Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Traders should monitor the ACC presentation for any data suggesting expanded clinical utility of VASCEPA, particularly in high-risk subgroups or via novel mechanisms like Lp(a) oxidation inhibition, which could influence future prescribing patterns or payer coverage, though no immediate revenue catalyst is expected.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$15.42
T+0 close · Mar 16, 2026 · via day close
Latest settled
−7.91%
T+60 · $14.20
Vs SPY
−18.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 16 $15.42entry
  2. T+1 · 8mo ago +0.65%α +0.38% · $15.52
  3. T+5 · 8mo ago −5.32%α −3.28% · $14.60
  4. T+20 · 7mo ago −5.64%α −9.42% · $14.55
  5. T+60 · 5mo ago −7.91%α −18.40% · $14.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Amarin Corporation announced that additional subgroup and mechanistic data from the REDUCE-IT trial will be presented at the American College of Cardiology's 2026 Scientific Session. The data include analyses on icosapent ethyl's efficacy in high-risk cardiovascular patients and its effect on lipoprotein(a) oxidation, reinforcing the drug's biologic activity beyond triglyceride lowering.

Key Facts

  • Additional REDUCE-IT subgroup and mechanistic data will be presented at ACC 2026 in New Orleans (March 28–30, 2026).
  • Oral presentation on icosapent ethyl efficacy in extreme cardiovascular risk patients scheduled for March 29.
  • Poster on EPA’s inhibition of oxidized lipoprotein(a) at elevated levels to be presented March 28.
  • No new financial results, guidance changes, regulatory decisions, or commercial updates were disclosed.
  • VASCEPA has been prescribed over 25 million times in the U.S. and is approved in multiple global markets.

Financial Impact

No immediate financial impact; data may support long-term clinical adoption and reimbursement discussions.

revenuemarket accessprescription volume

Risk Factors

  • No new efficacy or safety data beyond previously published REDUCE-IT results; limited incremental impact.
  • Forward-looking statements are speculative and subject to risks including competition, reimbursement challenges, and lack of strategic partnerships.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3256251

Track record

8 reports on AMRN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Oct 28, 202619d ago 8-K Neutral 5/10 No price data
  2. Oct 28, 202619d ago Press Release Neutral 5/10 Entry $12.75 Now $11.31 −11.26% settles Jan 26
  3. Oct 25, 202622d ago Press Release Mixed 6/10 Entry $12.09 Now $11.31 −6.45% settles Jan 22
  4. Aug 28, 202611w ago Press Release Neutral 4/10 Entry $13.97 Now $11.31 −19.04% settles Nov 23
  5. Jun 4, 202623w ago Court Ruling Bearish 7/10 Entry $13.80 to $13.97 Now $11.31 +18.04% ▼ −1.23% +0.65% vs SPY
  6. Apr 29, 202628w ago 8-K Neutral 4/10 Entry $14.29 to $13.55 Now $11.31 −20.85% ▼ −5.18% −9.29% vs SPY
  7. Mar 16, 202635w ago Press Release Neutral 4/10 Viewing Entry $15.42 to $14.20 Now $11.31 −26.65% ▼ −7.91% −18.40% vs SPY
  8. Feb 25, 202637w ago 8-K Bearish 6/10 Entry $14.05 to $14.27 Now $11.31 +19.50% ▼ −1.57% +5.38% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens Wed (11h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 16, 2026